Literature DB >> 14713563

Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.

Gary Ginsberg1, Dale Hattis, Abel Russ, Babasaheb Sonawane.   

Abstract

Children's risks can differ from those in adults for numerous reasons, one being differences in the pharmacokinetic handling of chemicals. Immature metabolism and a variety of other factors in neonates can affect chemical disposition and clearance. These factors can be incorporated into physiologically based pharmacokinetic (PBPK) models that simulate the fate of environmental toxicants in both children and adults. PBPK models are most informative when supported by empirical data, but typically pediatric pharmacokinetic data for toxicants are not available. In contrast, pharmacokinetic data in children are readily available for therapeutic drugs. The current analysis utilizes data for caffeine and theophylline, closely related xanthines that are both cytochrome P-450 (CYP) 1A2 substrates, in developing PBPK models for neonates and adults. Model development involved scale-up of in vitro metabolic parameters to whole liver and adjusting metabolic function for the ontological pattern of CYP1A2 and other CYPs. Model runs were able to simulate the large differences in half-life and clearance between neonates and adults. Further, the models were able to reproduce the faster metabolic clearance of theophylline relative to caffeine in neonates. This differential between xanthines was found to be due primarily to an extra metabolic pathway available to theophylline, back-methylation to caffeine, that is not available to caffeine itself. This pathway is not observed in adults exemplifying the importance of secondary or novel routes of metabolism in the immature liver. Greater CYP2E1 metabolism of theophylline relative to caffeine in neonates also occurs. Neonatal PBPK models developed for these drugs may be adapted to other CYP1A2 substrates (e.g., arylamine toxicants). A stepwise approach for modeling environmental toxicants in children is proposed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14713563     DOI: 10.1080/15287390490273550

Source DB:  PubMed          Journal:  J Toxicol Environ Health A        ISSN: 0098-4108


  34 in total

1.  What is the right dose for children?

Authors:  Massimo Cella; Catherijne Knibbe; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

2.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

Review 3.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 4.  Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

Authors:  Ronald N Hines; Dana Sargent; Herman Autrup; Linda S Birnbaum; Robert L Brent; Nancy G Doerrer; Elaine A Cohen Hubal; Daland R Juberg; Christian Laurent; Robert Luebke; Klaus Olejniczak; Christopher J Portier; William Slikker
Journal:  Toxicol Sci       Date:  2009-09-21       Impact factor: 4.849

Review 5.  State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.

Authors:  Venkata Yellepeddi; Joseph Rower; Xiaoxi Liu; Shaun Kumar; Jahidur Rashid; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447

6.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

7.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Behavioral profile assessment in offspring of Swiss mice treated during pregnancy and lactation with caffeine.

Authors:  Roberto Laureano-Melo; Anderson Luiz Bezerra da Silveira; Fernando de Azevedo Cruz Seara; Rodrigo Rodrigues da Conceição; Cláudio da Silva-Almeida; Bruno Guimarães Marinho; Fábio Fagundes da Rocha; Luís Carlos Reis; Wellington da Silva Côrtes
Journal:  Metab Brain Dis       Date:  2016-06-04       Impact factor: 3.584

Review 10.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.